Time filter

Source Type

Chen X.-F.,Jiangsu AoSaiKang Pharmaceutical Co. | Ma J.-J.,Jiangsu AoSaiKang Pharmaceutical Co.
Chinese Journal of New Drugs | Year: 2011

As a new generation of anti-cancer drugs, bendamustine has an obvious effect on a wide range of cancers. The clinical practice indicated that its monotherapy or combination therapy has a curative effect on non-Hodgkin's lymphoma, multiple myeloma, chronic lymphocytic leukemia and breast carcinoma. Besides, bendamustine significantly reduces the relapse rate and mortality with lower adverse reactions. It is safe and worthy of a wide use for cancer patients. This article summarized its pharmacology and the clinical research.


Song T.-T.,Jiangsu Aosaikang Pharmaceutical Co. | Feng J.-J.,Jiangsu Aosaikang Pharmaceutical Co. | Ma R.,Jiangsu Aosaikang Pharmaceutical Co.
Chinese Journal of New Drugs | Year: 2015

Isavuconazole is a novel broad-spectrum triazoleantifungal agent. It was granted the fast-track status and designated Qualified Infectious Disease Product (QIDP), and an orphan drug for the treatment of invasive aspergillosis and mucormycosis by the U.S. Food and Drug Administration (FDA). Isavuconazole demonstrated in vitro coverage of a broad range of yeasts (such as Candida species) and molds (such as Aspergillus species and Mucor species). Isavuconazole is administered as a water-soluble prodrug. Oral and intravenous formulations are available. Due to its prolonged half-life(iv: t1/2=76~104 h, po: t1/2=56~77 h), an once-a-day regimen is possible. In the phase III invasive aspergillosis study, isavuconazole demonstrated non-inferiority to voriconazole. Isavuconazole treatment-relevant adverse events were statistically fewer than voriconazole in the System Organ Classes of hepatobiliary, skin and eye disorders. Isavuconazole contains two adjacent chiral centers, some patents have reported in synthesis of enantiomerically pure compounds. In this article, in vitro antibacterial activity, pharmacokinetic, clinical study and chemical synthesis of isavuconazole were reviewed. ©, 2015, Chinese Journal of New Drugs Co. Ltd. All right reserved.


Zhao J.,Jiangsu Aosaikang Pharmaceutical Co. | Ma J.-J.,Jiangsu Aosaikang Pharmaceutical Co.
Chinese Journal of New Drugs | Year: 2012

Miriplatin is a third-generation platinum compound developed to treat hepatocellular carcinoma (HCC). It is administered via the hepatic artery using the carrier lipiodol that consists of ethyl esters of iodized poppy seed oil. Miriplatin has a high affinity for lipiodol and it is anticipated to exert antitumor effects with prolonged retention along with local lipiodol at the tumor site. Therefore, it is suggested that the active compound released from miriplatin/lipiodol can bind to DNA and produce a cytotoxic effect. The clinical research shows that miriplatin has beneficial curative effect and safety in the treatment of hepatocellular carcinoma. This article will summarize its pharmacology, pharmacokinetics, clinical research, and safety evaluation.


Chen X.,Jiangsu Aosaikang Pharmaceutical Co. | Du Y.,Jiangsu Aosaikang Pharmaceutical Co. | Sun H.,Jiangsu Aosaikang Pharmaceutical Co. | Wang F.,Jiangsu Aosaikang Pharmaceutical Co. | And 2 more authors.
Bioorganic and Medicinal Chemistry Letters | Year: 2014

Two series of novel tricyclic oxazine and oxazepine fused quinazolines have been designed and synthesized. The in vitro antitumor effect of the title compounds was screened on N87, A431, H1975, BT474 and Calu-3 cell lines. Compared to erlotinib and gefitinib, compounds 1a-1h were found to demonstrate more potent antitumor activities. Several derivatives could counteract EGF-induced phosphorylation of EGFR in cells, and their potency was comparable to the reference compounds. Compounds 1a-1h were chosen for further evaluation of EGFR and HER2 in vitro kinase inhibitory activity. Compounds 1b-1f, 1h effectively inhibited the in vitro kinase activity of EGFR and HER2 with similar efficacy as erlotinib and gefitinib. © 2014 Elsevier Ltd. All rights reserved.


Lu J.,China Pharmaceutical University | Kan S.,Jiangsu Aosaikang Pharmaceutical Co | Zhao Y.,China Pharmaceutical University | Zhang W.,China Pharmaceutical University | Liu J.,China Pharmaceutical University
Drug Development and Industrial Pharmacy | Year: 2016

The purpose of this study was to develop the novel naproxen/esomeprazole magnesium compound pellets (novel-NAP/EMZ) depending on EMZ acid-independent mechanism which has been proved to be predominate in the mechanism of co-therapy with nonsteroidal anti-inflammatory drug. The novel-NAP/EMZ compound pellets, composed of NAP colon-specific pellets (NAP-CSPs) and EMZ modified-release pellets (EMZ-MRPs), were prepared by fluid-bed coating technology with desired in vitro release profiles. The resulting pellets were filled into hard gelatin capsules for in vivo evaluation in rats and compared with the reference compound pellets, consisted of NAP enteric-coated pellets (NAP-ECPs) and EMZ immediate-release pellets (EMZ-IRPs). The reference compound pellets were prepared simulating the drug delivery system of VIMOVO®. In vivo pharmacokinetics, EMZ-MRPs had significantly larger AUC0– t (p < 0.01), 1.67 times more than that of EMZ-IRPs, and prolonged mean residence time (7.55 ± 0.12 h) than that of IRPs (1.46 ± 0.39 h). NAP-CSPs and NAP-ECPs showed similar AUC0– t. Compared to the reference compound pellets, the novel-NAP/EMZ compound pellets did not show distinct differences in histological mucosal morphology. However, biochemical tests exhibited enhanced total antioxidant capacity, increased nitric oxide content and reduced malondialdehyde level for novel-NAP/EMZ compound pellets, indicating that the acid-independent action took effect. The gastric pH values of novel-NAP/EMZ compound pellets were at a low and stable level, which could ensure normal physiological range of human gastric pH. As a result, the novel-NAP/EMZ compound pellets may be a more suitable formulation with potential advantages by improving bioavailability of drug and further reducing undesirable gastrointestinal damages. © 2016 Taylor & Francis


Dong J.,China Pharmaceutical University | Gong Y.,China Pharmaceutical University | Liu J.,China Pharmaceutical University | Chen X.,Jiangsu Aosaikang Pharmaceutical Co. | And 2 more authors.
Bioorganic and Medicinal Chemistry | Year: 2014

All eight stereoisomers of saxagliptin have been synthesized and evaluated for their inhibitory activity against DPP-IV. It was unambiguously confirmed that the configuration of saxagliptin was critical to potent inhibition of DPP-IV. Docking study was performed to elucidate the configuration-activity relationship of saxagliptin stereoisomers. Tyr662 and Tyr470 have been suggested as the key residues of DPP-IV interacting with the inhibitors. This work provides valuable information for further inhibitor design against DPP-IV. © 2014 Elsevier Ltd. All rights reserved.


Jin X.-F.,Jiangsu Aosaikang Pharmaceutical Co. | Chen Q.-C.,Jiangsu Aosaikang Pharmaceutical Co. | Zong Z.-W.,Jiangsu Aosaikang Pharmaceutical Co. | Xu Y.,Jiangsu University
Chinese Journal of New Drugs | Year: 2013

Drug-eluting beads (DEB) not only combine the dual effects of arterial embolization and targeted chemotherapy, but also can release drug slowly and continuously into lesions and maintain therapeutic drug concentration for a long time. Compared to conventional transcatheter arterial chemoembolization, DEB demonstrate a significant advantage in effect-enhancing and toxicity-reducing action and have showed encouraging results in treatment of hepatocelluar carcinoma. In this review, several properties of beads in geometry, biology and physics were briefly discussed; besides, the frontier research advances of DEB also were introduced, together with clinical research progresses of gelatin microspheres, DC Bead® and HepaSphere® as the carriers of chemotherapeutic drugs. At last, this review also summarized some shortcomings of DEB in drug-loading mechanism, bead size, bead material and so on and proposed directions for future development.


Trademark
Jiangsu Aosaikang Pharmaceutical; Co. | Date: 2012-10-24

Medicines for human purposes for the treatment of gastrointestinal diseases; dietetic food preparations, namely, crackers adapted for medical purposes; tonics medicine for human purposes for the treatment of gastrointestinal diseases; milk powder for infants; dental lacquer; disinfecting paper tissue impregnated with disinfecting chemicals or compounds therefor for use on railings, countertops and toilet seats; first aid kits; depuratives for the body; preparations for destroying vermin. Chemical research; cosmetic research; chemical analysis; chemistry services; biological research; bacteriological research; research and development for others; quality checking and testing; industrial design; computer software consultancy. Health care; physical therapy; pharmaceutical advice; services of a psychologist, namely, psychological counseling; guidance on diet nutrition; landscape gardening; animal breeding; pharmacists services to make up prescriptions; health spa services, namely, health spa services for health and wellness of the body and spirit; telemedicine services.


Sun M.,Jiangsu Aosaikang Pharmaceutical Co. | Zhao J.,Jiangsu Aosaikang Pharmaceutical Co. | Chen X.,Jiangsu Aosaikang Pharmaceutical Co. | Zong Z.,Jiangsu Aosaikang Pharmaceutical Co. | And 4 more authors.
Bioorganic and Medicinal Chemistry Letters | Year: 2016

Two series of novel tricyclic oxazine and oxazepine fused quinazolines have been designed and synthesized. The in vitro antitumor effect of the title compounds was screened on N87, A431, H1975, BT474 and Calu-3 cell lines. Compared to gefitinib and erlotinib, compounds . 1a-1h were found to demonstrate more potent antitumor activities. Several derivatives could counteract EGF-induced phosphorylation of EGFR in cells, and their potency was comparable to the reference compounds. Compounds . 1a-1f, . 1h were chosen for further evaluation of EGFR and HER2 in vitro kinase inhibitory activity. Compounds . 1c-1f, . 1h effectively inhibited the in vitro kinase activity of EGFR and HER2 with similar efficacy as gefitinib and erlotinib. © 2016 Elsevier Ltd.


Ma R.,Jiangsu Aosaikang Pharmaceutical Co. | Song T.-T.,Jiangsu Aosaikang Pharmaceutical Co. | Feng J.-J.,Jiangsu Aosaikang Pharmaceutical Co.
Chinese Journal of New Drugs | Year: 2014

The American Journal Science has named cancer immune therapy as the last year's most groundbreaking scientific achievement. Blocking immune checkpoint pathways is regard as one of the most promising treatments in cancer immune therapy at now. Over the last several years, monoclonal antibodies, such as the anti-cytotoxic T-lymphocyte antigen-4 antibody (ipilimumab), anti-programmed cell death-1 antibody (nivolumab), and anti-programmed cell death-1 ligand antibody (MPDL3280A), which inhibit immune-checkpoint pathways, have been tested in clinical trials. These immune-checkpoint inhibitors have made significant progress in lung cancer therapy. In this article, the clinical trials of immune checkpoint inhibitors for lung cancer therapy were reviewed. ©, 2014, Chinese Journal of New Drugs Co. Ltd. All right reserved.

Loading Jiangsu Aosaikang Pharmaceutical Co. collaborators
Loading Jiangsu Aosaikang Pharmaceutical Co. collaborators